Partnership & Product Launch

Advanced Medical Solutions Grp PLC
08 November 2006



For immediate release                                            8 November 2006




                         Advanced Medical Solutions Group plc

                            ('AMS' or 'the Company')



                      Partnership with BSN medical and AT3



                 European launch of novel wound closure product





Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
medical technology company, today announces that it has entered into a
partnership with AT3, a Canadian technology company, and BSN medical, a global
medical device company, for manufacturing and distribution of Leukosan(R)
SkinLink, a novel wound closure product.



Leukosan(R) SkinLink consists of a perforated adhesive closure strip on which
cyanoacrylate topical glue is applied to produce a non-invasive system for
closing trauma wounds in Accident and Emergency and surgical incisions in the
Operating Room.  SkinLink offers significant benefits over current closure
methods such as sutures, staples or strips. This strong wound closure system is
as reliable as conventional methods, yet requires no anesthesia, stitching or
stapling and therefore adds no further trauma to the wound. This patented wound
closing procedure is easy to learn and quick to apply and represents a
significant time saving in the closure and overall treatment of cuts and
incisions.



Montreal based AT3 owns the Intellectual Property rights covering SkinLink.  AMS
has been granted exclusive distribution rights to the UK and an exclusive
manufacturing licence to supply the product for other markets.  BSN medical of
Hamburg, Germany, acquired an exclusive marketing licence for the product for
all European countries outside the UK. BSN medical has recently launched
SkinLink throughout Europe under its Leukosan(R) brand and plans to market it in
more than twenty countries around the world.



Commenting on today's announcement Dr. Don Evans, Chief Executive of AMS,
stated:



'I am pleased that we have been able to obtain exclusive manufacturing rights to
this novel technology.  We have been selling this product in the UK since 2005
as part of our wound closure portfolio and look forward to supplying BSN medical
across the world.'



Jean Matteau, President of AT3, added:



'We are delighted to have signed licensing deals with companies of the calibre
of AMS and BSN medical which provides strong validation of our SkinLink
technology, confirming our own experience in Canada.'



Dr. Claus Wiegel, Global Commercial Director of BSN medical, said:



'The launch plans were very ambitious and we are pleased that we were able to
meet the expectations thanks to the joint effort of this international
partnership.'



                                     -ENDS-





For further information, please contact:


Advanced Medical Solutions Group plc                   Tel : [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com


Buchanan Communications                                Tel: [phone]
Mark Court, Mary-Jane Johnson



Notes to Editors:



Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $13 billion global woundcare market. Founded in
1991 and currently quoted on AIM, Advanced Medical Solutions is focused on the
design, development and manufacture of innovative and technologically advanced
products for woundcare and other medical applications.



In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.



The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives that offer benefits over sutures and
staples for closing wounds sold direct to hospitals or through distributors.



AMS's technology and products currently serve the majority of the key global
markets and strategic partners.



AT3 is a privately held company of new medical technologies who acquired the
Intellectual Property covering SkinLink at the beginning of 2006. The company
has successfully developed a competitive and patent protected wound closure
device which represent the next generation of skin closure technology.  AT3's
vision is to establish its skin closure system as the new standard of care for
closing surgical incisions and traumatic wounds.



BSN medical is a global leader in the worldwide healthcare market specializing
in the areas of Wound Care, Orthopaedics and Phlebology. The company is focused
on the development of world-class branded products which offer high quality
solutions for caregivers and patients.



BSN medical was originally formed as a joint venture in 2001 between Beiersdorf,
Inc. and Smith & Nephew, Inc. In early 2006, BSN medical became a fully
independent player. BSN medical employs almost 3500 people worldwide and
maintains manufacturing facilites in Germany, France, Mexico, New Zealand, South
Africa, the UK, the US and other countries; sales and marketing organisations
operate in the largest markets.




                      This information is provided by RNS
            The company news service from the London Stock Exchange